You are here: Industry Insights > Autoimmune Diseases

News List

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases Biotech Newswire
July 09, 2024
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.
SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases B3C newswire
November 16, 2023
SciRhom GmbH, a pioneering biotech enterprise specialized in developing first-in-class therapeutic antibodies, announced today the achievement of a significant milestone in its development pipeline.
Maxion Therapeutics Awarded £2 Million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-To-Treat" Autoimmune Diseases PharmaSources
April 20, 2023
Maxion therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “Hard-To-Treat" autoimmune diseases.
GentiBio raises $157m to develop Treg therapies for autoimmune diseases pharmaceutical-technology
August 13, 2021
GentiBio has raised $157m in a Series A funding round led by Matrix Capital Management to progress its new pipeline of engineered regulatory T cell (Treg) treatments in immunology.
Exagen to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection americanpharmaceuticalreview
November 11, 2020
Exagen announced a new study in collaboration with Brigham and Women’s Hospital in Boston, MA. This study will evaluate the incidence and risk factors for onset of rheumatic autoimmune diseases in people who recovered from COVID-19.
BioMed X Starts New Research Program in Autoimmune Diseases with Merck b3cnewswire
January 17, 2020
BioMed X announced today the start of a new joint research group in collaboration with Merck. With this new group, BioMed X and Merck extend their ongoing collaboration to a total of six joint research projects at the BioMed X Innovation Center in Heidelb
SciRhom Initiates First-In-Class Antibody Development Program to Treat Major Autoimmune Diseases b3cnewswire
November 06, 2019
SciRhom GmbH, a therapeutic antibody company, announced the development of first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways ...
Parvus Therapeutics, Genetech collaborate for autoimmune diseases biospectrumasia
May 20, 2019
Parvus Eligible to Receive Upfront and Milestone Payments Exceeding $800 Million Plus Royalties on Net Sales
Eli Lilly inks deal with ImmuNext to jointly develop therapies for autoimmune diseases firstwordpharma
March 28, 2019
Eli Lilly and ImmuNext announced a collaboration to jointly study a preclinical novel target that could facilitate the development of new treatments for autoimmune disorders that regulate immune cell metabolism.
Calypso Biotech BV Secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases b3cnewswire
March 01, 2019
Calypso Biotech, an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing co-led by Gilde Healthcare and Inkef Capital. They are joined by Johnson & Johnson Innovatio